Melatonin Supreme Time Release
Natural health product licensed in Canada
- Other names
- Health First Melatonin Supreme
- Licence holder
- Health First Network
- NPN or DIN-HM
- 80090303
- Status
- Active licence
- Licence date
- 25 January 2019
- Revision date
- Not provided
- Form
- Comprimé
- Route of administration
- Orale
- Application type
- Officinale
If this product were sold in France
No point flagged by the rules we apply.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| N-[2-(5-méthoxy-1H-indol-3-yl)éthyl]acétamide Source : Mélatonine | 3 milligramme | Not calculated |
Non-medicinal ingredients
Phosphate de dicalcium dihydraté, Stéarate de magnésium, Hypromellose, Cellulose microcristalline
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | minimum: 19 years | 1 Comprimé | 1 day |
Uses authorised in Canada
Helps to increase the total sleep time (aspect of sleep quality) in people suffering from sleep restriction or altered sleep schedule (e.g. shift work, jet lag). Helps to prevent and/or reduce the effects of jet lag/minimize jet lag (e.g. daytime fatigue, sleep disturbance) (for people traveling by plane easterly across two or more time zones/if flying east over two or more time zones). Helps to speed up/ reduce the time it takes to fall asleep (sleep onset latency aspect of sleep quality) in people who fall asleep slowly/with delayed sleep phase disorder. Helps to re-set the body's sleep-wake cycle (aspect of the circadian rhythm).
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
- Contre-indications
Do not use this product if you are pregnant or breastfeeding.
- Effets indésirables connus
Stop use if allergy occurs or if you experience headache, confusion, or nausea.
- Précautions et mises en garde
Consult your health care practitioner/health care provider/health care professional/doctor/ physician if sleeplessness persists for more than 4 weeks (chronic insomnia). Avoid taking with alcohol or products that increase drowsiness. Consult a health care practitioner/health care provider/health care professional/doctor/ physician prior to use if you are taking medications for seizure, blood pressure, to suppress the immune system (immunosuppressive medications), to affect mental state or increase sedation, steroids or blood thinners. Consult a health care practitioner/health care provider/health care professional/doctor/ physician prior to use if you have cardiovascular, immune, liver or chronic kidney disease, hormonal or seizure disorders, asthma, depression, diabetes, low blood sugar, or migraine.
Source
Official Health Canada record, licence 80090303
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.